期刊
JOURNAL OF CANCER
卷 12, 期 7, 页码 1936-1944出版社
IVYSPRING INT PUBL
DOI: 10.7150/jca.53675
关键词
FSCN; multiple myeloma; biomarker; prognosis
类别
资金
- Medical Scientific Research Foundation of Guangdong Province, China [A2019472, A2018031]
- Xinjiang Joint Fund of National Natural Science Foundation of China [U1903117]
- National Natural Science Foundation of China [81500118, 81970193]
- Guangdong Basic and Applied Basic Research Foundation [2019A1515011327]
- Fundamental Research Funds for the Central Universities [19ykpy39]
The study demonstrated that FSCN1 was significantly down-regulated in MM and high expression of FSCN1 and FSCN2 were associated with longer overall survival (OS) in MM patients. FSCN1 and FSCN2 could serve as favorable prognostic factors for predicting clinical outcomes in MM, and their combination could effectively predict longer event-free survival (EFS) and OS.
Multiple myeloma (MM) is a hematologic tumor with monoclonal proliferation of malignant plasma cells in the bone marrow. Fascin (FSCN) is an actin-binding protein that plays a crucial role in cell migration and invasion, contributing to tumor metastasis. There are three members (FSCN1-3) in FSCN family. However, the prognostic role of FSCN family in MM remains unclear. In this study, we used four independent Gene Expression Omnibus (GEO) datasets to explore the relationships between FSCN1-3 expression profiles and patient survival in MM. We found that FSCN1 was dramatically down-regulated in MM compared to normal donors (p < 0.001) and monoclonal gammopathy of undetermined significance (MGUS) (p = 0.032). Patients with high expression of FSCN1 and FSCN2 had significantly longer OS (p = 0.023 and 0.028, respectively). Univariate and multivariate analysis showed that FSCN1 (p = 0.003, 0.002) and FSCN2 (p = 0.018, 0.013) were independent favorable prognostic factors for OS in MM. Moreover, the combination of high expression of FSCN1 and FSCN2 could effectively predict both longer EFS (p = 0.046) and OS (p = 0.015). Our study suggested that FSCN1 and FSCN2 can be used as favorable biomarkers for predicting clinical outcomes in MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据